Presented at the IASCLC 2020 North America Conference on Lung Cancer, October 16 to October 17, 2020.
Percy P. Lee1, Leigh Boehmer2, Matthew Smeltzer3, Brendon M. Stiles4
1Department of Radiation Oncology, University of Texas MD Anderson Cancer Center; 2Association of Community Cancer Centers; 3Division of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health; 4Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital
Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease that often elicits differing opinions regarding what is “unresectable”, depending upon the specialist and the treatment setting. Using survey data, we sought to characterize opinions regarding the resectability of stage III NSCLC.
This project is made possible by support from AstraZeneca.